View on Pubmed.gov 33803291 | View on doi.org 10.3390/microor...
Identification of New Potential Biotherapeutics from Human Gut Microbiota-Derived Bacteria.
- U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, CNRS, Inserm, CHU Lille, Université de Lille, 59000 Lille, France. Institut Micalis, MIHA Team, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, France.
- Institut Micalis, MIHA Team, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, France. Laboratoire de Biotechnologie et Microbiologie des Aliments, UFR en Sciences et Technologies des Aliments, Université Nangui Abrogoua, Abidjan 00225, Côte d'Ivoire.
- U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, CNRS, Inserm, CHU Lille, Université de Lille, 59000 Lille, France.
- Institut Micalis, MIHA Team, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, France.
- CRNH-O Mass Spectrometry Core Facility, 44000 Nantes, France.
- Faculté de Pharmacie de Paris, UMR-S1139 INSERM, Université de Paris, 75006 Paris, France.
Abstract
The role of the gut microbiota in health and disease is well recognized and the microbiota dysbiosis observed in many chronic diseases became a new therapeutic target. The challenge is to get a better insight into the functionality of commensal bacteria and to use this knowledge to select live biotherapeutics as new preventive or therapeutic products. In this study, we set up a screening approach to evaluate the functional capacities of a set of 21 strains isolated from the gut microbiota of neonates and adults. For this purpose, we selected key biological processes involved in the microbiome-host symbiosis and known to impact the host physiology i.e., the production of short-chain fatty acids and the ability to strengthen an epithelial barrier (Caco-2), to induce the release of the anti-inflammatory IL-10 cytokine after co-culture with human immune cells (PBMC) or to increase GLP-1 production from STC-1 endocrine cell line. This strategy highlighted fifteen strains exhibiting beneficial activities among which seven strains combined several of them. Interestingly, this work revealed for the first time a high prevalence of potential health-promoting functions among intestinal commensal strains and identified several appealing novel candidates for the management of chronic diseases, notably obesity and inflammatory bowel diseases.
References
Front Microbiol. 2020 Jun 10;11:1121
Future Sci OA. 2020 Mar 30;6(6):FSO474
Cell Rep. 2019 Jan 2;26(1):222-235.e5
Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S119-21; discussion S144-51
Cited by 32 citations (total)
Journal Article
Maternal prebiotic supplementation impacts colitis development in offspring mice.
Electronic publication date January 24, 2023
Amélie Lê [...] Malvyne Rolli-Derkinderen et al.
Background and aims
Maternal diet plays a key role in preventing or contributing to the development of chronic diseases, such as...
Journal Article Review
Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions.
Electronic publication date October 12, 2022
Duygu Ağagündüz [...] Raffaele Capasso et al.
Probiotics have been defined as "living microorganisms that create health benefits in the host when taken in sufficient amounts. Recent...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •